Pertussis, known also as whooping cough, is a highly communicable infectious disease of the respiratory tract caused by airborne
exposure to Bordetella pertussis, a gram-negative bacillus. In addition to the coughing and choking spells that make breathing difficult, major complications—most
common among infants and young children—include hypoxia, apnea, pneumonia, seizures, encephalopathy, and malnutrition. In
a teleconference conducted recently by the National Foundation for Infectious Diseases, several physicians discussed the new
adult recommendations for pertussis booster vaccinations.
Katrina Kretsinger, M.D., a medical epidemiologist and lieutenant commander with the U.S. Public Health Service, said, "Pertussis
is the most poorly controlled preventable disease in this country. It is typically considered a childhood disease; thus many
adult providers may not think of pertussis at all, even when an adult presents with a very typical classic case."
Pertussis can be especially serious for infants less than a year old; it may even be fatal. Prior to the 1940s, pertussis
was a dreaded disease that claimed thousands of lives—mostly infants and young children. However, with the availability of
childhood vaccines, its incidence has decreased. But even the reported occurrence of pertussis cases is not a good representation
of the actual number. In 2004, approximately 26,000 cases of pertussis were reported in the United States, with adults accounting
for a third of those cases. Kretsinger, along with William Schaffner, M.D., professor and chairman, department of preventative
medicine, Vanderbilt University School of Medicine, reported an estimated 600,000 cases of pertussis every year in the adult
population. The underreporting of the disease is likely due to the fact that some states report only culture-positive cases,
making it hard to predict the true burden of the disease.
The Centers for Disease Control & Prevention recommends the primary series of an acellular pertussis vaccine in combination
with diphtheria and tetanus toxoids (DTaP) for all infants at two, four, and six months of age. Additional doses of the DTaP
vaccine are recommended at 15 to 18 months and at four to six years.
The Food & Drug Administration has licensed two new vaccines for a single booster immunization against pertussis, in combination
with tetanus and diphtheria (Tdap). Boostrix (GlaxoSmithKline Biologicals) was licensed on May 3, 2005, for use in adolescents
10-18 years old. Adacel (Sanofi Pasteur) was licensed on June 10, 2005, for persons 11-64 years of age. These are the first
pertussis booster vaccines to be licensed in adolescents and adults. Recently, the CDC Advisory Committee on Immunization
Practices (ACIP) voted that adults from 19 to 64 years of age should be vaccinated with the Tdap vaccine. Under the new ACIP
recommendation, Tdap would replace the tetanus-diphtheria vaccine now recommended and used as an adult booster.
The new vaccine would reduce the risk of transmitting the disease to infants. Adults can transmit the bacterium to infants
too young to start the vaccine or children who have not completed the series, said Schaffner.
Russell Steele, M.D., professor and vice chairman of pediatrics at Louisiana State University School of Medicine, said the
impact on infants is of greatest concern, as they are more susceptible to death and complicated infections.
Pertussis is highly contagious, with up to 90% of susceptible household contacts developing clinical disease following exposure
to an index case. "These new recommendations are highly vital to protecting both adults and children because of the high contagiousness,"
he said.
To prevent disease transmission, a community must be immunized. The first step is to vaccinate all children on time with the
primary series of the vaccine. In Canada's four-year experience with the vaccine, the incidence of pertussis has decreased
from 12 cases per 10,000 people to one case per 40,000 people. Kretsinger added that by stocking and administering the vaccine
as indicated, discussing the importance of the vaccine with patients, and asking patients if they are up to date on their
tetanus vaccine or if they are in close contact with infants, healthcare providers can play an active role in reducing the
incidence, and preventing the spread, of pertussis.
The Author is a healthcare writer based in northern New Jersey.